After Tariff Flush, a Fresh Look at AbbVie Pharma (ABBV)

Group 1 - AbbVie Pharmaceuticals (NYSE: ABBV) is primarily involved in immunology, oncology, neuroscience, eye care, and virology, and is the parent company of Allergan, known for Botox [2] - The stock has shown significant support at the 23-month moving average, with a notable low of 164.39 on April 9th [2] - A potential long-term double bottom is indicated by the November 2024 low, suggesting a favorable outlook for the stock [3] Group 2 - A close over 178 would confirm a reversal pattern for AbbVie, although it is currently underperforming compared to the SPY [6] - The company faces challenges from pharmaceutical tariffs and must overcome several resistance hurdles, including the January 6-month calendar range high and the 200-DMA [6] - The current market phase is distribution, which is considered better than bearish, indicating some positive momentum [6]